Opko Health Shares Jump Over 33% Following Strong Earnings

American biopharmaceutical and diagnostics company Opko Health surprised investors today, Tuesday, as its stock jumped 33.33% to 500 agorot on the Tel Aviv Stock Exchange. The surge follows the release of the company's financial reports for the second quarter of 2026, published on Monday.

Revenue totaled 163.5 million dollars, a 4.3% increase compared to 156.8 million dollars in the same quarter last year. This figure significantly exceeded analysts' forecasts, which stood at approximately 131 million dollars. The company's market value in Tel Aviv reached approximately 2.7 billion shekels.

The company reported a quarterly loss of 0.01 dollars per share, outperforming the analysts' forecast of a 0.08 dollar loss. This is a marked improvement from the 0.19 dollar loss per share recorded in the same period last year, representing an earnings surprise of 87.50%. Notably, the company has beaten earnings per share forecasts in three of the last four quarters.

Operating loss narrowed to 7 million dollars from 60 million dollars, aided by an 18.1 million dollar profit from asset sales. Net loss stood at 8.4 million dollars, or one cent per share, compared to 148.4 million dollars and 19 cents per share in the corresponding quarter last year.

In the pharmaceutical sector, revenue reached 89 million dollars, with product sales contributing 42.9 million dollars. Service revenue decreased to 74.5 million dollars. Operating profit totaled 4.8 million dollars, while expenses dropped to 69.8 million dollars from 119.3 million dollars.

Another catalyst for the stock's rise is the updated guidance. Opko Health management now estimates 2026 revenue to range between 560 million and 585 million dollars, up from the previous forecast of 530–560 million dollars. This guidance exceeds the consensus estimate of approximately 536 million dollars.